Skip to main content
Full access
New Research
Published Online: 31 October 2014

Identification and Replication of a Combined Epigenetic and Genetic Biomarker Predicting Suicide and Suicidal Behaviors

Abstract

Considerable research suggests that suicide involves effects of genes, the environment, and their interaction. Analysis of three independent data sets of post-mortem brains revealed signs of increased methylation in one particular gene, SKA2, a finding that was extended to peripheral blood samples from other cohorts of prospectively followed individuals.

Abstract

Objective:

Reliable identification of individuals at high risk for suicide is a priority for suicide prevention. This study was conducted to identify genes exhibiting epigenetic variation associated with suicide and suicidal behaviors.

Method:

Genome-wide DNA methylation profiling was employed separately on neuronal and glial nuclei in a discovery set of postmortem brains from the National Institute of Child Health and Human Development to identify associations with suicide. Pyrosequencing-based validation was conducted in prefrontal cortical tissue in cohorts from the Stanley Medical Research Institute and Harvard Brain Bank at McLean Hospital and peripheral blood from three living groups. Functional associations with gene expression, stress and anxiety, and salivary cortisol were assessed.

Results:

The DNA methylation scan identified an additive epigenetic and genetic association with suicide at rs7208505 within the 3′ untranslated region of the SKA2 gene independently in the three brain cohorts. This finding was replicated with suicidal ideation in blood from three live cohorts. SKA2 gene expression was significantly lower in suicide decedents and was associated with genetic and epigenetic variation of rs7208505, possibly mediated by interaction with an intronic microRNA, miR-301a. Analysis of salivary cortisol measurements suggested that SKA2 epigenetic and genetic variation may modulate cortisol suppression, consistent with its implicated role in glucocorticoid receptor transactivation. SKA2 significantly interacted with anxiety and stress to explain about 80% of suicidal behavior and progression from suicidal ideation to suicide attempt.

Conclusions:

These findings implicate SKA2 as a novel genetic and epigenetic target involved in the etiology of suicide and suicidal behaviors.
Suicide is a complex, heterogeneous phenotype as well as an intractable public health problem, with the overall annual suicide rate remaining stable over the past 60 years at around 10 to 12 per 100,000 (1). The National Action Alliance for Suicide Prevention has set out to build a research agenda with the potential to reduce our national suicide rate by 20% within 5 years (2). One strategy proposed is to identify and target subgroups at greatest risk. Heuristic models outlining the chain of events leading to suicide often include biological or genetic characteristics, early life events including trauma and other stressors, impulsive aggressive traits, psychopathology, inadequate social support, and access to lethal means (35).
A growing body of evidence suggests that suicide vulnerability may be due to epigenetic alterations in molecular pathways important for hypothalamic-pituitary-adrenal (HPA) axis function. For example, DNA methylation changes in the NR3C1 gene, which encodes the glucocorticoid receptor, are altered by maternal behavior in rats (6) and are higher than normal in the hippocampus of suicide decedents who experienced early life trauma (7). The cumulative effect of these epigenetically mediated events is a reduction in glucocorticoid receptor levels, possibly leading to impaired responses to stressors. Suicidal individuals exhibit less ability to suppress cortisol after experimental administration of the synthetic glucocorticoid dexamethasone (8), and the cortisol stress response has been identified as one of the most promising candidate suicide endophenotypes (3). Other studies have provided evidence that first-degree relatives of suicide decedents fail to mount a proper HPA axis response to stress (9). Such findings are consistent with the diathesis-stress or dual-risk hypothesis, whereby an underlying biological state moderates an aberrant response to stress (1014). Identification of the underlying genetic and epigenetic factors influencing vulnerability to suicidal behaviors in the context of stressors is needed to maximize suicide prevention efforts.
The objective of this study was to use genome-wide screening techniques to identify novel epigenetic associations in postmortem brain tissue of suicide decedents, followed by replication and functional assessment of identified loci. A secondary objective was to assess the degree to which identified loci would be present in peripheral blood samples and to evaluate their biomarker efficacy in the context of stress and anxiety.

Method

Human Samples

Postmortem prefrontal cortical tissue samples were obtained from the National Institute of Child Health and Human Development (NICHD) Brain and Tissue Bank for Developmental Disorders at the University of Maryland (20), the Stanley Medical Research Institute, and the Harvard Brain Bank at McLean Hospital. Peripheral blood was obtained from three Johns Hopkins studies of participants who consented to blood drawing for future research, including the Genetics of Recurrent Early-Onset Depression (GenRED) offspring (15, 16), the Prevention Research Center study participants (17, 18), and a prospective cohort of pregnant women described previously (19). Descriptions of the cohorts can be found in Table 1 and in Figure S1 and the supplementary methods in the data supplement accompanying the online version of this article.
TABLE 1. Characteristics of Subjects in Postmortem and Living Cohorts Examined for Epigenetic and Epigenetic Biomarkers of Suicide or Suicidal Behavior
Sample Type, Cohort,a and Diagnostic GroupNSuicidal BehaviorAge (years)SexSubstance UsebPsychiatric MedicationPostmortem Interval (hours)
YesNoMeanSDMFYesNoYesNoMeanSD
Postmortem brain; suicide assessed             
NICHD             
 Major depression2921832.015.91415920121718.107.1
 Control group2922732.116.1141522702916.145.0
Stanley Medical Research Institute             
 Bipolar disorder28131546.111.1131524327139.2119.7
 Control group2902943.87.7227161302929.1013.7
 Schizophrenia2962343.16.622719829031.8616.1
McLean             
 Bipolar disorder124860.520.0751118421.0710.5
 Control group1201261.716.2844801221.335.7
Blood from live subjects             
GenRED offspring (15, 16)             
 Bipolar disorder1  21 011001  
  Suicidal ideation 10          
  Suicide attempt 10          
 Major depression8  18.13.0622617  
  Suicidal ideation 35          
  Suicide attempt 26          
 Control group13  15.32.35801349  
  Suicidal ideation 310          
  Suicide attempt 112          
Prospective cohort of pregnant women (19); suicidal ideation assessed             
 Bipolar disorder1431129.36.401411386  
 Major depression37102731.56.40371362512  
Prevention Research Center study (17, 18)             
 Major depression30  29.61.211191713  
  Suicidal ideation 2010          
  Suicide attempt 1515          
 Control group295  30.52.611717870225  
  Suicidal ideation 59236          
  Suicide attempt 33262          
a
NICHD, National Institute of Child Health and Human Development; McLean, Harvard Brain Bank at McLean Hospital; GenRED, Genetics of Recurrent Early-Onset Depression.
b
Data were missing for some subjects.

Procedures

Genome-wide DNA methylation data were obtained from Illumina HM450 microarrays (Illumina, San Diego) previously generated by our group (20), for which data are located under Gene Expression Omnibus accession GSE15745. A discovery set of NICHD prefrontal cortical tissue data was created from 10 Caucasian individuals with major depression for whom bulk tissue data were available; seven died by suicide, and three did not. A replication set consisted of the remaining eight suicide and four nonsuicide samples from Caucasians with major depression in the NICHD cohort not originally interrogated.
Pyrosequencing was conducted in microarray-identified loci in all individuals in Table 1. All SKA2 gene expression data and rs7208505 genotyping was performed by using quantitative real-time polymerase chain reaction (PCR). Detailed methodological information, including salivary cortisol analysis for the GenRED offspring, is available in the supplementary methods and Table S1 in the online data supplement.

Statistical Analysis

Unless otherwise stated, the reported statistics derive from linear regression analysis, adjusted for age, sex, race, and postmortem interval (in brain cohorts), generated in R (http://www.r-project.org/). Relevant additional covariates were adjusted according to the strategy presented in the online supplementary methods information (Table S2). Using the Cramer–von Mises test, we subsequently evaluated all data distributions that rejected the null hypothesis of normality with nonparametric tests. All statistical tests were two tailed, with p≤0.05 denoting statistical significance. Microarray analysis employed false discovery rate correction for multiple testing. Where specified, genotype correction of SKA2 3′ untranslated region (UTR) DNA methylation was achieved by taking the residuals of a linear model of SKA2 3′ UTR DNA methylation as a function of rs7208505 genotype. Randomization was employed within all experimental processing batches. Personnel performing laboratory experiments were blind to caseness.

Results

Genome-Wide DNA Methylation Analysis and Replication

We performed a genome-wide screen for DNA methylation variation associated with suicide in a small discovery set of postmortem prefrontal cortical tissue from the NICHD cohort. Using a linear model adjusting for age and sex as covariates, we identified four loci significantly associated with suicide after correction for multiple testing, corresponding to the ATP8A1 (cg24533989), SKA2 (cg13989295), LOC153328 (cg15918259), and KCNAB2 (cg17106415) genes (Figure 1A). Using fluorescence-activated cell sorting, we separated neuronal and glial nuclei as described previously (20), after which only SKA2 exhibited nominal significance in the neuronal and glial fractions of both the discovery and replication sets (Figure 1B). The identified cytosine-guanine (CpG) dinucleotide is located on the antisense strand of chromosome 17 at position 57187729 (hg19) within the 3′ UTR of the SKA2 (spindle and kinetochore associated complex subunit 2) gene, which encodes a scaffold protein implicated in chaperoning the glucocordicoid receptor into the nucleus (21). It is important to note that the cytosine (C) at this position represents the alternative allele of single-nucleotide polymorphism (SNP) rs7208505, while the reference allele is a thymine (T). Also, the T allele abrogates the CpG dinucleotide and cannot be methylated. The assessment of rs7208505 epigenetic and genetic variation in an additive linear model demonstrated significant associations of both model terms with suicide across the entire NICHD cohort of 23 suicide cases and 35 comparison cases independent of ethnicity or DSM-IV diagnosis (Table 2). These associations were replicated in two independent cohorts of postmortem prefrontal cortical samples from the Stanley Medical Research Institute cohort and the Harvard Brain Bank at McLean Hospital cohort (Figure 1E, Table 2) and did not appear to be related to the mode of death (Result S1 in the supplementary results section of the data supplement accompanying the online version of this article).
FIGURE 1. Discovery and Functional Analysis of SKA2 Gene As Epigenetic Biomarker of Suicide or Suicidal Behavior
a Volcano plot of DNA methylation differences, based on a linear model (x axis) and negative natural log of the p value (y axis), for postmortem brains from seven suicide and three nonsuicide subjects with major depression from the National Institute of Child Health and Development (NICHD) generated in bulk tissue. Loci remaining significant after false discovery rate correction appear above the dashed line, identifying significant hits at ATP8A1 (F=3424.5, df=3, 6, p<0.001), SKA2 (F=1101.7, df=3, 6, p<0.001), LOC153328 (F=384.3, df=3, 6, p<0.001), and KCNAB2 (F=243.5, df=3, 6, p<0.001).
b Significant differences in DNA methylation for the cg13989295 Illumina probe within the SKA2 3′ untranslated region (UTR) for the discovery sample neurons (F=784.3, df=3, 6, p<0.001), discovery sample glia (F=421.3, df=3, 6, p<0.001), replication sample neurons (F=2.2, df=3, 8, p=0.04), and replication sample glia (F=3.2, df=3, 8, p=0.02). Error bars represent standard deviations; large error bars derive from unaccounted-for variation in rs7208505 genotype.
c Significant differences in SKA2 gene expression in prefrontal cortical samples between 23 suicide and 35 comparison subjects from the NICHD cohort (Wilcoxon rank sum test: W=97, df=49.91, p<0.001). Error bars represent standard deviations.
d Uncorrected DNA methylation levels at rs7208505. Error bars represent standard deviations. Associated significance metrics are presented in Table S4 of the data supplement accompanying the online version of this article. NICHD, National Institute of Child Health and Human Development; Stanley Institute, Stanley Medical Research Institute; McLean, Harvard Brain Bank at McLean Hospital; GenRED, Genetics of Recurrent Early-Onset Depression (15, 16); Prospective Study, prospective cohort of pregnant women (19); Prevention Study, Prevention Research Center study (17, 18).
e Genotype-corrected DNA methylation levels at rs7208505. Error bars represent standard deviations. Associated significance metrics are located in Table 2. Abbreviations are provided in the preceding footnote.
* p≤0.05.
TABLE 2. Epigenetic and Genetic Effects of SKA2 rs7208505 on Suicide and Suicidal Behavior in Postmortem and Living Cohorts
 Subjects     Model
Sample Type, Cohort,a and Model TermsNRisk VariableβErrorpFdfR2p
Postmortem brain         
NICHD, neurons58Suicide   2.28, 480.27<0.05
 DNA methylation  0.030.010.03    
 rs7208505 C/T  –0.580.270.04    
 rs7208505 C/Cb  –1.500.570.04    
 Age  –0.010.0040.02    
 Sex  –0.080.130.54    
 Postmortem interval  0.020.010.09    
Stanley Medical Research Institute86Suicide   2.410, 750.240.02
 DNA methylation  0.010.0030.02    
 rs7208505 C/T  –0.300.130.03    
 rs7208505 C/Cb  –0.470.220.04    
 Age  –0.000.010.44    
 Sex  0.170.090.07    
 Postmortem interval  0.0040.0030.17    
McLean24Suicide   8.36, 170.75<0.001
 DNA methylation  0.090.020.002    
 rs7208505 C/T  –3.400.960.003    
 rs7208505 C/Cb  –7.101.900.002    
 Age  –0.010.0030.0002    
 Sex  0.040.110.75    
 Postmortem interval  –0.010.010.35    
Blood from live subjects         
GenRED offspring (15, 16)22Suicidal ideation   2.06, 120.500.14
 DNA methylation  0.170.07<0.05    
 rs7208505 C/T  –6.503.100.06    
 rs7208505 C/Cb  –15.006.70<0.05    
 Age  0.030.040.41    
 Sex  –0.090.210.69    
Prospective cohort of pregnant women (19)51Suicidal ideation   2.78, 420.340.02
 DNA methylation  0.070.02<0.001    
 rs7208505 C/T  –3.001.000.005    
 rs7208505 C/Cb  –6.101.800.002    
 Age  0.020.020.41    
 Sex         
Prevention Research Center study (17, 18)325Suicidal ideation   3.910, 3140.11<0.001
 DNA methylation  0.0020.001<0.05    
 rs7208505 C/T  –0.050.060.40    
 rs7208505 C/Cb  –0.140.100.16    
 Age  0.010.010.51    
 Sex  –0.0020.050.97    
a
NICHD, National Institute of Child Health and Human Development; McLean, Harvard Brain Bank at McLean Hospital; GenRED, Genetics of Recurrent Early-Onset Depression.
b
Alternative homozygote.

Gene Expression and Functional Relevance of Identified Locus

In the NICHD brain cohort, SKA2 exhibited significantly lower gene expression values in the suicide cases than in the comparison cases (Figure 1C). SKA2 expression was significantly negatively associated with DNA methylation both before and after we controlled for rs7208505 variation, while genotype alone was not associated (Figure S2A and Table S3 in the online data supplement).
To understand the effects of 3′ UTR epigenetic variation on expression, we correlated rs7208505 variation with all other CpGs located across SKA2 by using available microarray data. Significant correlations were observed in neuronal but not glial DNA in two regions including promoter CpGs flanking a binding site for the CREB transcription factor and upstream of an intronic microRNA, miR-301a (online supplement: Figure S2 and Result S2). Epigenetic variation in these regions showed opposing effects on SKA2 gene expression (Figure S2 and Result S2). Average levels of DNA methylation of CpGs in the region upstream of miR-301a were lower in glial than in neuronal DNA, possibly accounting for the neuron-specific associations observed in this region (online supplement: Figure S2E). Together, rs7208505 epigenetic and genetic variation interacted with promoter and miR-301a proximal epigenetic variation to explain 40% of SKA2 gene expression, whereas 16% was explained by the model with rs7208505 variation alone (online supplement: Table S3).

Replication in Peripheral Tissues

We assessed the association of SKA2 variation with suicidal ideation in peripheral blood samples from the three living cohorts. Across all cohorts, significant rs7208505 DNA methylation elevations were observed, consistent with the brain findings (Figures 1D and 1E, Table 2, online Table S4, online Result S3). Model factors were significant among the 30 women in the prospective cohort who provided blood samples months before the suicidal ideation measurement (online supplement: Table S5, Result S4), suggesting that SKA2 3′ UTR DNA methylation variation (relevant to suicidal ideation) preceded the transition to suicidal ideation. Weighted gene coexpression network analysis (22) in brain- and blood-derived data provided supporting evidence that peripheral epigenetic variation is a marker of primarily neuronal processes (online supplement: Result S5).

Association of SKA2 With Salivary Cortisol

Using prospectively recorded cortisol measurements in the GenRED offspring cohort, we assessed the ability of SKA2 3′ UTR epigenetic and genetic variation to mediate suppression of cortisol levels. Waking cortisol level was significantly associated with suicidal ideation in this cohort; however, cortisol measured at 30 or 60 minutes was not associated, nor were CpGs in the region directly upstream of rs7208505 (online supplement: Figure S4A, Result S6). Only waking cortisol was significantly associated with epigenetic variation at rs7208505 (online supplement: Table S6, Figure S4B); however, as SKA2 is implicated in glucocorticoid signaling, we reasoned that cortisol levels may interact with SKA2 to mediate suppression of future cortisol. Prospectively investigated interaction of waking cortisol with SKA2 3′ UTR epigenetic and genetic variation was significantly associated with the reduced suppression of cortisol from the 30 to 60 minute time points (online Table S6). SKA2-mediated changes in glucocorticoid signaling may influence and interact with other suicidal-ideation-related biological variation, such as promoter CpGs in the SAT1 gene (online supplement: Result S7 and Figures S4C and S4D) where gene expression has been previously implicated in suicidal behavior (23).

Interaction of SKA2 With Anxiety and Stress

We observed a significant interaction of both perceived stress scores and anxiety scores with rs7208505 genotype and DNA methylation in predicting third-trimester suicidal ideation from first- and second-trimester blood in the prospective cohort (Table 3, online Figure S5). This association was replicated in the GenRED offspring cohort, where anxiety interacted with rs7208505 epigenetic and genetic status to moderate suicide attempt but not suicidal ideation (Table 3). In the Prevention Research Center cohort, the anxiety interaction model was associated with suicidal ideation; however, the association became even stronger in the subset with suicide attempts (Table 3, online Figure S5). The interaction of SKA2 3′ UTR DNA methylation with anxiety had a nearly significant association with suicide attempt in those with suicidal ideation (online Table S6). Finally, a nonsignificant interaction between DNA methylation and anxiety was observed with the metric “intent to die” among individuals who had attempted suicide (Table S6). Cumulatively, our data suggest that epigenetic variation at SKA2 could increase risk for suicidal ideation and that among individuals with suicidal ideation also experiencing anxiety or stress, a suicide attempt is more likely.
TABLE 3. Effects on Suicidal Behavior of Interactions Between Anxiety and SKA2 rs7208505 in Three Living Cohorts
 Subjects     Model
Cohort and Model TermsaNRisk VariableβErrorpFdfR2p
Prospective cohort of pregnant women (19)30Suicidal ideation   6.810, 170.80<0.001
 DNA methylation  –0.070.050.14    
 rs7208505 C/T  2.662.320.27    
 rs7208505 C/Cb  6.304.420.17    
 Anxiety  –0.130.130.31    
 Age  0.010.010.48    
 Sex         
 Interaction         
  DNA methylation with anxiety  0.050.020.007    
  C/T genotype with anxiety  –1.920.780.03    
  C/C genotype with anxiety  –4.181.460.02    
GenRED offspring (15, 16)22Suicide attempt   4.39, 120.800.02
 DNA methylation  0.010.040.89    
 rs7208505 C/T  –0.231.600.89    
 rs7208505 C/Cb  –0.343.500.92    
 Anxiety  –0.320.300.30    
 Age  0.040.030.15    
 Sex  0.210.130.14    
 Interaction         
  DNA methylation with anxiety  0.210.080.02    
  C/T genotype with anxiety  –7.803.200.04    
  C/C genotype with anxiety  –18.007.100.03    
Prevention Research Center study (17, 18)325Suicidal ideation   2.612, 3120.090.003
 DNA methylation  0.0010.0010.37    
 rs7208505 C/T  –0.020.060.79    
 rs7208505 C/Cb  –0.050.110.66    
 Anxiety  0.150.150.32    
 Age  0.0040.010.66    
 Sex  –0.030.050.58    
 Interaction         
  DNA methylation with anxiety  0.010.0040.04    
  C/T genotype with anxiety  –0.390.240.10    
  C/C genotype with anxiety  –0.980.410.02    
Prevention Research Center study (17, 18)325Suicide attempt   1.912, 3120.070.04
 DNA methylation  0.00040.0010.70    
 rs7208505 C/T  –0.010.050.79    
 rs7208505 C/Cb  0.050.090.54    
 Anxiety  –0.110.120.36    
 Age  0.0020.010.83    
 Sex  –0.010.040.87    
 Interaction         
  DNA methylation with anxiety  0.010.0040.004    
  C/T genotype with anxiety  –0.110.200.57    
  C/C genotype with anxiety  –0.950.340.006    
a
GenRED, Genetics of Recurrent Early-Onset Depression. Definitions of anxiety are given in the “Study metrics” section of the data supplement accompanying the online version of this article. Race was adjusted for in all models, but the data are not shown because of space limitations.
b
Alternative homozygote.

Prediction of Suicidal Behavior

We assessed the ability of our statistical model to predict suicidal ideation in peripheral tissues of living individuals. We used suicide attempt data from the Prevention Research Center cohort to generate an additive linear model of rs7208505 genotype and SKA2 3′ UTR DNA methylation interacting with anxiety status, controlling for age and sex as covariates. With anxiety status used as the interactive covariate, the model predicted suicidal ideation in the GenRED cohort with an area under the receiver operator characteristic curve (AUC) of 0.71 (95% CI=0.42–1.00); however, use of salivary cortisol level as the interactive covariate improved the AUC to 0.82 (95% CI=0.60–1.00) (Figure 2A). In the prospective sample, the perceived stress metric at the time of blood drawing was used as the interactive covariate, resulting in an AUC for prediction of suicidal ideation of 0.80 (95% CI=0.64–0.97) (Figure 2A). Limiting the women in the prospective study to the 30 for whom third-trimester suicidal ideation was predicted from first- or second-trimester blood generated an AUC of 0.79 (95% CI=0.42–1.00) (Figure 2B). Increasing the stringency of the threshold to define suicidal ideation (see supplementary methods in the online data supplement) resulted in improved model performance across both comparisons in this cohort (all women: N=51, AUC=0.91, 95% CI=0.8–1.00; first- or second-trimester women: N=30, AUC=0.96, 95% CI=0.89–1.00). In the GenRED cohort, the model predicted the four suicide attempters from the group with an AUC of 0.97 (95% CI=0.89–1.00) (Figure 2B).
FIGURE 2. Prediction of Suicidal Behavior by Interaction of Anxiety With SKA2 3′ UTR DNA Methylation and SKA2 rs7208505 Genotype in Two Living Cohortsa
a Data on suicide attempts from the Prevention Research Center study (17, 18) were used to generate an additive linear model of the interaction of anxiety status with SKA2 3′ untranslated region (UTR) DNA methylation and rs7208505 genotype, with age and sex covariates controlled for. Receiver operator characteristic (ROC) curves depict the sensitivity as a function of the specificity for predictions of suicidal ideation or behavior. GenRED, Genetics of Recurrent Early-Onset Depression (15, 16); prospective cohort, prospective cohort of pregnant women (19). Definitions of anxiety are given in the “Study metrics” section of the data supplement accompanying the online version of this article.
b ROC curves are shown for suicide attempts in the GenRED offspring cohort (N=4) and for women in the prospective cohort for whom suicidal ideation in the third trimester was predicted from blood sampled in the first or second trimester.

Discussion

Using microarray technology to scan for epigenetic suicide associations, we identified a significant effect in a very small group of suicide decedents. The effect size of about 55% DNA methylation difference at SKA2 enabled this small study group to have adequate power to survive correction for multiple testing, which was driven by the underlying genetic status of the rs7208505 SNP, which abrogates the CpG dinucleotide. While microarray analysis was performed only in Caucasians, incorporation of both the genetic and epigenetic variation at this locus enabled replication across the entirety of the NICHD cohort, two additional postmortem brain cohorts, and three blood cohorts. Despite the consistency of the findings, the relatively small sizes of the studied cohorts suggest they represent promising but preliminary results warranting further study. The presented linear models suggested that DNA methylation and rs7208505 genotype may have opposing effects on suicidal behavior; however, as these metrics were highly correlated, the protective effects of rs7208505 may represent a statistical artifact. Analysis of genetic and epigenetic effects on suicidal behavior and gene expression separately indicated that DNA methylation alone may be the primary factor conferring risk. It is important that the overall proportion of DNA methylation at rs720505 increased significantly with each successive C-containing allele, suggesting that the underlying genetic architecture at rs7208505 may confer vulnerability by providing a genetic template for methylation changes to occur. This risk template would be expected to vary as a function of ethnicity, as allele frequencies for the C-containing allele of rs7208505 are reportedly much lower in African Americans (about 18%) than in other ethnicities (50%−60%). Cumulatively, numerous consistent associations were observed with suicidal ideation, suicide attempt, and suicide completion, independent of variation in ethnicity and psychiatric diagnosis, suggesting that variation in SKA2 may mediate risk for suicidal behaviors that progress from ideation to attempt to suicide.
SKA2 may influence suicidal phenotypes through its role in chaperoning the glucocorticoid receptor from the cytoplasm to the nucleus. Rice et al. (21) demonstrated that knockdown of SKA2 eliminated glucocorticoid receptor transactivation and response to dexamethasone treatment in vitro and that protein levels of SKA2 were decreased by glucocorticoid treatment, suggesting that SKA2 gene expression may be a component of the glucocorticoid feedback inhibition system. In our data, SKA2 genetic and epigenetic differences were associated with reduced suppression of salivary cortisol after waking in the GenRED cohort. As the blood was not drawn at the same time as the salivary cortisol sampling, the causative role of DNA methylation must be interpreted cautiously. While DNA methylation variation at rs7208505 might be important for suicidal ideation etiology, it remains possible that this variation is a reflection of cortisol variation.
In the proposed model, SKA2 epigenetic and genetic variation represents an underlying state increasing suicide risk in the presence of a stressor. SKA2 epigenetic and genetic variation interacted with stress and anxiety metrics to mediate suicidal ideation in the prospective cohort, while in the Prevention Research Center and GenRED offspring cohorts, the same model distinguished individuals with suicidal ideation who transitioned to suicide attempt. It is important to note that the suicidal ideation, suicide attempt, and suicide phenotypes are not interchangeable; however, in some individuals they represent progressive stages of suicidal behavior that share many etiological factors. The proportion of variance accounted for by our models was very high in some cohorts and leaves little room for the involvement of other factors. While our data suggest that SKA2 may be etiologically relevant to glucocorticoid signaling, it is possible that the detected epigenetic variation at SKA2 also represents a molecular record of suicide-dysregulated glucocorticoid load over time and thus may be reflective of other sources of etiologically relevant variation at other loci implicated in suicide. In a recent study, blood gene expression at SAT1 prospectively predicted both suicidal ideation and suicide attempt (23). Our supplemental analysis demonstrated an interaction between SKA2 variation and DNA methylation at a CpG in the SAT1 promoter located within a region enriched for glucocorticoid receptor binding. SKA2-mediated failure to suppress normal stress response may play a role in SAT1 gene expression variation and could contribute to the transition from suicidal ideation to suicide attempt. Cumulatively, our data are consistent with findings from an epidemiological study of 108,664 individuals in 21 countries that found disorders characterized by anxiety and poor impulse control predicted the transition from suicidal ideation to suicide attempt (24).
One caveat with these analyses is that different metrics of suicidal ideation, suicide attempt, stress, and anxiety were available across the studied cohorts. In the Prevention Research Center and prospective study groups, anxiety was measured by response to a single question, while the Screen for Child Anxiety Related Disorders (SCARED) was used for the GenRED offspring. In the prospective cohort, we showed that anxiety, as measured by the Edinburgh Postnatal Depression Scale, was highly associated with perceived stress, which in another study was correlated with salivary cortisol level (25). Thus, it is possible that the observed interactions of SKA2 with anxiety across cohorts are a reflection of underlying differences in stress and HPA axis response in anxious individuals. Despite these limitations, the ability of the linear model generated from the Prevention Research Center cohort to accurately predict both suicidal ideation and suicide attempt in the prospective and GenRED cohorts suggests that consistency was captured by these diverse metrics.
The lower SKA2 gene expression in NICHD brains from suicide decedents was associated primarily with isolated neuronal nuclei, suggesting the epigenetic dysregulation may be confined to neurons. The postmortem brain data were generated in the prefrontal cortex, a brain region with inhibitory connections to the HPA axis (26, 27) and responsible for decision making, inhibition of negative thoughts, and impulsivity (28, 29). Low glucocorticoid receptor transactivation is consistent with current models of suicide diathesis, as experimentally reduced glucocorticoid receptor gene expression in rodents mimics suicidal human characteristics (8), producing increases in corticosterone and helplessness in response to stress (30).
The influence of SKA2 3′ UTR epigenetic variation on gene expression appeared to be mediated by interaction with epigenetic variation within the gene promoter and proximal to intronic miR-301a, which has previously been shown to be low in the postmortem prefrontal cortex of individuals who die by suicide (31). Critically, miR-301a modulates SKA2 gene expression in A549 cell models by indirectly inhibiting CREB binding to the SKA2 promoter (32), while the promoter CpGs shown to correlate with rs7208505 DNA methylation directly flank this CREB binding site. As would be expected given the model, we observed a significant effect of the interaction of miR-301a and promoter CpG variation on SKA2 expression. The observed correlations of SKA2 3′ UTR DNA methylation with other CpGs across the gene could result from common epigenetic reprogramming effects of glucocorticoid receptor binding, as the regions demonstrating correlations were located within glucocorticoid receptor immunoprecipitation peaks identified from Encyclopedia of DNA Elements (ENCODE) data. It is also possible that miR-301a proximal genetic variation in linkage disequilibrium with rs7208505 serves to alter glucocorticoid receptor recruitment, subsequently reprogramming DNA methylation in the region, as discussed in the online supplementary material. The miR-301a is an intronic microRNA and requires mRNA transcription of SKA2 to be generated by Drosha, an RNase III enzyme (33). DNA methylation upstream of miR-301a may therefore result in cotranscriptional slowing and allow for spliceosomal interaction as occurs with inclusion of methylated alternative exons in alternatively spliced genes (34). Elevated neuronal but not glial DNA methylation levels proximal to miR-301a suggest a possible functionally different effect of miR-301a in these two cell types. It is important to note that while epigenetic variation proximal to the miR-301a and CREB binding site was associated with SKA2 gene expression, it was not associated with suicidal phenotype.
While a growing number of studies are investigating epigenetic alterations in suicide (23, 3540), few studies have identified biomarkers with high prediction accuracy. To our knowledge, the biomarker identified in this study represents the first genetic and epigenetic biomarker capable of predicting suicidal ideation and suicide attempt in a prospective manner with over 80% accuracy from blood. The model performed remarkably well at predicting suicide attempt in the GenRED cohort; however, with only four attempters, this result should be interpreted with caution. While the Prevention Research Center cohort contained many more suicide attempt cases, we did not test prediction in this cohort as the time between suicide attempt and blood draw was greater than 10 years on average. Accumulating epigenetic change due to stochastic drift, substance use, and errors in retrospective reporting would call into question the reliability of the prediction. However, this highlights the fact that the cause versus effect of prediction accuracy in the GenRED offspring cohort must also be interpreted with care as the blood was taken after the suicide attempt. Nevertheless, our data demonstrate similar accuracies when predicting suicidal ideation in a prospective manner, suggesting that SKA2 epigenetic and genetic variation may represent a trait influencing underlying suicide risk when interacting with stress. Cumulatively, the clinical implications of this finding are that early screening of those at risk for suicidal ideation and suicide attempt may be possible, allowing for the identification of individuals at risk, proactive treatment, and stress and anxiety reduction. The potential efficacy of this biomarker is relevant to numerous populations, for example, the military, where the identification of an underlying vulnerability may identify individuals at risk for developing suicidal behaviors when exposed to the stress of war-time situations. Future studies should be carried out to further evaluate the prospective efficacy of this finding in additional populations.

Footnote

The authors thank the Stanley Medical Research Institute and the Harvard Brain Bank at McLean Hospital for providing DNA to enable replication of the findings and Douglas Granger at the Center for Interdisciplinary Salivary Bioscience Research at Johns Hopkins for generation of the salivary cortisol data.

Supplementary Material

File (appi.ajp.2014.14010008.ds001.pdf)
File (appi.ajp.2014.14010008_ds001.pdf)

References

1.
Centers for Disease Control and Prevention, National Centers for Injury Prevention and Control: Web-Based Injury Statistics Query and Reporting System (WISQARS), 2013. www.cdc.gov/ncipc/wisqars
2.
Pringle B, Colpe LJ, Heinssen RK, Schoenbaum M, Sherrill JT, Claassen CA, Pearson JL: A strategic approach for prioritizing research and action to prevent suicide. Psychiatr Serv 2013; 64:71–75
3.
Mann JJ, Arango VA, Avenevoli S, Brent DA, Champagne FA, Clayton P, Currier D, Dougherty DM, Haghighi F, Hodge SE, Kleinman J, Lehner T, McMahon F, Mościcki EK, Oquendo MA, Pandey GN, Pearson J, Stanley B, Terwilliger J, Wenzel A: Candidate endophenotypes for genetic studies of suicidal behavior. Biol Psychiatry 2009; 65:556–563
4.
McGirr A, Turecki G: The relationship of impulsive aggressiveness to suicidality and other depression-linked behaviors. Curr Psychiatry Rep 2007; 9:460–466
5.
Shaffer D, Craft L: Methods of adolescent suicide prevention. J Clin Psychiatry 1999; 60(suppl 2):70–74
6.
Zhang TY, Parent C, Weaver I, Meaney MJ: Maternal programming of individual differences in defensive responses in the rat. Ann N Y Acad Sci 2004; 1032:85–103
7.
McGowan PO, Sasaki A, D’Alessio AC, Dymov S, Labonté B, Szyf M, Turecki G, Meaney MJ: Epigenetic regulation of the glucocorticoid receptor in human brain associates with childhood abuse. Nat Neurosci 2009; 12:342–348
8.
Coryell W, Schlesser M: The dexamethasone suppression test and suicide prediction. Am J Psychiatry 2001; 158:748–753
9.
McGirr A, Diaconu G, Berlim MT, Pruessner JC, Sablé R, Cabot S, Turecki G: Dysregulation of the sympathetic nervous system, hypothalamic-pituitary-adrenal axis and executive function in individuals at risk for suicide. J Psychiatry Neurosci 2010; 35:399–408
10.
Mann JJ, Waternaux C, Haas GL, Malone KM: Toward a clinical model of suicidal behavior in psychiatric patients. Am J Psychiatry 1999; 156:181–189
11.
Belsky J, Pluess M: Beyond diathesis stress: differential susceptibility to environmental influences. Psychol Bull 2009; 135:885–908
12.
Obradović J, Bush NR, Stamperdahl J, Adler NE, Boyce WT: Biological sensitivity to context: the interactive effects of stress reactivity and family adversity on socioemotional behavior and school readiness. Child Dev 2010; 81:270–289
13.
Boyce WT, Ellis BJ: Biological sensitivity to context, I: an evolutionary-developmental theory of the origins and functions of stress reactivity. Dev Psychopathol 2005; 17:271–301
14.
Sameroff A: Developmental systems: contexts and evolution, in Handbook of Child Psychology, Vol 1. Edited by Mussen P. New York, Wiley, 1983, pp 237–294
15.
Levinson DF, Zubenko GS, Crowe RR, DePaulo RJ, Scheftner WS, Weissman MM, Holmans P, Zubenko WN, Boutelle S, Murphy-Eberenz K, MacKinnon D, McInnis MG, Marta DH, Adams P, Sassoon S, Knowles JA, Thomas J, Chellis J: Genetics of Recurrent Early-Onset Depression (GenRED): design and preliminary clinical characteristics of a repository sample for genetic linkage studies. Am J Med Genet B Neuropsychiatr Genet 2003; 119B:118–130
16.
Shi J, Potash JB, Knowles JA, Weissman MM, Coryell W, Scheftner WA, Lawson WB, DePaulo JR Jr, Gejman PV, Sanders AR, Johnson JK, Adams P, Chaudhury S, Jancic D, Evgrafov O, Zvinyatskovskiy A, Ertman N, Gladis M, Neimanas K, Goodell M, Hale N, Ney N, Verma R, Mirel D, Holmans P, Levinson DF: Genome-wide association study of recurrent early-onset major depressive disorder. Mol Psychiatry 2011; 16:193–201
17.
Kellam SG, Werthamer-Larsson L, Dolan LJ, Brown CH, Mayer LS, Rebok GW, Anthony JC, Laudolff J, Edelsohn G: Developmental epidemiologically based preventive trials: baseline modeling of early target behaviors and depressive symptoms. Am J Community Psychol 1991; 19:563–584
18.
Kellam SG, Rebok GW, Ialongo N, Mayer LS: The course and malleability of aggressive behavior from early first grade into middle school: results of a developmental epidemiologically-based preventive trial. J Child Psychol Psychiatry 1994; 35:259–281
19.
Guintivano J, Arad M, Gould TD, Payne JL, Kaminsky ZA: Antenatal prediction of postpartum depression with blood DNA methylation biomarkers. Mol Psychiatry 2014; 19:560–567; correction, 2014; 19:633
20.
Guintivano J, Aryee MJ, Kaminsky ZA: A cell epigenotype specific model for the correction of brain cellular heterogeneity bias and its application to age, brain region and major depression. Epigenetics 2013; 8:290–302
21.
Rice L, Waters CE, Eccles J, Garside H, Sommer P, Kay P, Blackhall FH, Zeef L, Telfer B, Stratford I, Clarke R, Singh D, Stevens A, White A, Ray DW: Identification and functional analysis of SKA2 interaction with the glucocorticoid receptor. J Endocrinol 2008; 198:499–509
22.
Langfelder P, Horvath S: WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics 2008; 9:559
23.
Le-Niculescu H, Levey DF, Ayalew M, Palmer L, Gavrin LM, Jain N, Winiger E, Bhosrekar S, Shankar G, Radel M, Bellanger E, Duckworth H, Olesek K, Vergo J, Schweitzer R, Yard M, Ballew A, Shekhar A, Sandusky GE, Schork NJ, Kurian SM, Salomon DR, Niculescu AB 3rd: Discovery and validation of blood biomarkers for suicidality. Mol Psychiatry 2013; 18:1249–1264
24.
Nock MK, Hwang I, Sampson N, Kessler RC, Angermeyer M, Beautrais A, Borges G, Bromet E, Bruffaerts R, de Girolamo G, de Graaf R, Florescu S, Gureje O, Haro JM, Hu C, Huang Y, Karam EG, Kawakami N, Kovess V, Levinson D, Posada-Villa J, Sagar R, Tomov T, Viana MC, Williams DR: Cross-national analysis of the associations among mental disorders and suicidal behavior: findings from the WHO World Mental Health Surveys. PLoS Med 2009; 6:e1000123
25.
Bougea AM, Spandideas N, Alexopoulos EC, Thomaides T, Chrousos GP, Darviri C: Effect of the emotional freedom technique on perceived stress, quality of life, and cortisol salivary levels in tension-type headache sufferers: a randomized controlled trial. Explore (NY) 2013; 9:91–99
26.
Shonkoff JP, Garner AS; Committee on Psychosocial Aspects of Child and Family Health; ; Committee on Early Childhood, Adoption, and Dependent Care; ; Section on Developmental and Behavioral Pediatrics: The lifelong effects of early childhood adversity and toxic stress. Pediatrics 2012; 129:e232–e246
27.
Turecki G, Ernst C, Jollant F, Labonté B, Mechawar N: The neurodevelopmental origins of suicidal behavior. Trends Neurosci 2012; 35:14–23
28.
Balleine BW, O’Doherty JP: Human and rodent homologies in action control: corticostriatal determinants of goal-directed and habitual action. Neuropsychopharmacology 2010; 35:48–69
29.
van den Bos W, Güroglu B: The role of the ventral medial prefrontal cortex in social decision making. J Neurosci 2009; 29:7631–7632
30.
Ridder S, Chourbaji S, Hellweg R, Urani A, Zacher C, Schmid W, Zink M, Hörtnagl H, Flor H, Henn FA, Schütz G, Gass P: Mice with genetically altered glucocorticoid receptor expression show altered sensitivity for stress-induced depressive reactions. J Neurosci 2005; 25:6243–6250
31.
Smalheiser NR, Lugli G, Rizavi HS, Torvik VI, Turecki G, Dwivedi Y: MicroRNA expression is down-regulated and reorganized in prefrontal cortex of depressed suicide subjects. PLoS ONE 2012; 7:e33201
32.
Cao G, Huang B, Liu Z, Zhang J, Xu H, Xia W, Li J, Li S, Chen L, Ding H, Zhao Q, Fan M, Shen B, Shao N: Intronic miR-301 feedback regulates its host gene, ska2, in A549 cells by targeting MEOX2 to affect ERK/CREB pathways. Biochem Biophys Res Commun 2010; 396:978–982
33.
Morlando M, Ballarino M, Gromak N, Pagano F, Bozzoni I, Proudfoot NJ: Primary microRNA transcripts are processed co-transcriptionally. Nat Struct Mol Biol 2008; 15:902–909
34.
Choi JK: Contrasting chromatin organization of CpG islands and exons in the human genome. Genome Biol 2010; 11:R70
35.
Bani-Fatemi A, Gonçalves VF, Zai C, de Souza R, Le Foll B, Kennedy JL, Wong AH, De Luca V: Analysis of CpG SNPs in 34 genes: association test with suicide attempt in schizophrenia. Schizophr Res 2013; 147:262–268
36.
Keller S, Sarchiapone M, Zarrilli F, Tomaiuolo R, Carli V, Angrisano T, Videtic A, Amato F, Pero R, di Giannantonio M, Iosue M, Lembo F, Castaldo G, Chiariotti L: TrkB gene expression and DNA methylation state in Wernicke area does not associate with suicidal behavior. J Affect Disord 2011; 135:400–404
37.
Labonté B, Suderman M, Maussion G, Lopez JP, Navarro-Sánchez L, Yerko V, Mechawar N, Szyf M, Meaney MJ, Turecki G: Genome-wide methylation changes in the brains of suicide completers. Am J Psychiatry 2013; 170:511–520
38.
Labonte B, Yerko V, Gross J, Mechawar N, Meaney MJ, Szyf M, Turecki G: Differential glucocorticoid receptor exon 1(B), 1(C), and 1(H) expression and methylation in suicide completers with a history of childhood abuse. Biol Psychiatry 2012; 72:41–48
39.
Murphy TM, Mullins N, Ryan M, Foster T, Kelly C, McClelland R, O’Grady J, Corcoran E, Brady J, Reilly M, Jeffers A, Brown K, Maher A, Bannan N, Casement A, Lynch D, Bolger S, Buckley A, Quinlivan L, Daly L, Kelleher C, Malone KM: Genetic variation in DNMT3B and increased global DNA methylation is associated with suicide attempts in psychiatric patients. Genes Brain Behav 2013; 12:125–132
40.
Fiori LM, Turecki G: Epigenetic regulation of spermidine/spermine N1-acetyltransferase (SAT1) in suicide. J Psychiatr Res 2011; 45:1229–1235

Information & Authors

Information

Published In

Go to American Journal of Psychiatry
Go to American Journal of Psychiatry
American Journal of Psychiatry
Pages: 1287 - 1296
PubMed: 25073599

History

Received: 2 January 2014
Revision received: 2 April 2014
Revision received: 7 May 2014
Accepted: 19 May 2014
Published ahead of print: 31 October 2014
Published online: 1 December 2014
Published in print: December 01, 2014

Authors

Details

Jerry Guintivano, Ph.D.
From the Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, and the Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore.
Tori Brown
From the Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, and the Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore.
Alison Newcomer, M.Sc.
From the Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, and the Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore.
Marcus Jones
From the Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, and the Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore.
Olivia Cox, B.Sc.
From the Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, and the Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore.
Brion S. Maher, Ph.D.
From the Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, and the Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore.
William W. Eaton, Ph.D.
From the Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, and the Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore.
Jennifer L. Payne, M.D.
From the Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, and the Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore.
Holly C. Wilcox, Ph.D.
From the Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, and the Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore.
Zachary A. Kaminsky, Ph.D.
From the Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, and the Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore.

Notes

Address correspondence to Dr. Kaminsky ([email protected]).

Funding Information

Drs. Wilcox and Kaminsky are listed as co-inventors on a patent to evaluate risk of suicidal behavior using genetic and epigenetic variation at the SKA2 locus. Dr. Payne received legal consulting fees from Pfizer, AstraZeneca, and Johnson and Johnson and research support from Corcept Therapeutics. The other authors report no financial relationships with commercial interests.Supported in part by NIMH grant MH-094771 to Dr. Kaminsky, the Johns Hopkins Center for Mental Health Initiatives, the Solomon R. and Rebecca D. Baker Foundation, and the James Wah Award for Mood Disorders; subjects were collected with funding from the American Foundation for Suicide Prevention to Dr. Wilcox, National Institute on Drug Abuse grant DA-09897 to Dr. Eaton, and NIMH grant MH-074799 to Dr. Payne; human subjects research for the GenRED offspring cohort, prospective cohort, and PRC cohort was conducted under IRB protocols 00015387, 00008149, and 000000354; and human tissue was obtained from the National Institute of Child Health and Human Development’s Brain and Tissue Bank for Developmental Disorders and the University of Maryland, Baltimore.

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

View Options

View options

PDF/EPUB

View PDF/EPUB

Get Access

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login
Purchase Options

Purchase this article to access the full text.

PPV Articles - American Journal of Psychiatry

PPV Articles - American Journal of Psychiatry

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share